FDA Drug · D-0848-2026

Lidocaine Ointment USP, 5%, Speermint Flavor, 50 g Jar, Rx only, Mfd. by: Taro Pharmaceuticals Inc., Brampton, Ontario, L6T1C, Canada, Dist By: Taro Pharmaceuticals U.S.A. Inc. Hawthorne NY 70532 NDC: 51672-3008-5

Class II · Ongoing

Failed Content Uniformity Specifications. Out of Specification for Assay during analysis at the 24- month long term stability station, at (25¿C,60%RH).

Affected lots / codes — check yours against thisLot # AD48154, Exp: 4/30/2027.

Recalling firm: SUN PHARMA /TARO, Hawthorne, NY
Classification: Class II (temporary or reversible harm possible)
Status: Ongoing
Quantity: 65,328 50g jars
Distribution: Nationwide in the USA
Recall initiated: August 31, 2026
Classified: September 15, 2026
Initiation: Voluntary: Firm initiated

Official source. This record is published by the U.S. FDA through the openFDA enforcement database. View the unmodified government record:
https://api.fda.gov/drug/enforcement.json?search=recall_number%3A%22D-0848-2026%22

Important. Recalls target specific lots and codes — compare the affected lots above against your own product. This page reproduces public FDA data for readability; EveryRecall is independent and not affiliated with the FDA.

Check this brand across all 8 databases →